Results 211 to 220 of about 18,017 (247)

Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors

Bioorganic & Medicinal Chemistry Letters, 2003
Factor Xa (fXa) is an important serine protease in the blood coagulation cascade. Inhibition of fXa has emerged as an attractive target for potential therapeutic applications in the treatments of both arterial and venous thrombosis. Herein, we describe a series of non-benzamidine isoxazoline derivatives as fXa inhibitors.
Mimi L, Quan, Christopher D, Ellis, Ming Y, He, Ann Y, Liauw, Patrick Y S, Lam, Karen A, Rossi, Robert M, Knabb, Joseph M, Luettgen, Matthew R, Wright, Pancras C, Wong, Ruth R, Wexler   +10 more
openaire   +2 more sources

Factor Xa Inhibitors

2022
Lee, Chase, Rea, Jack, Wise, Audrey, Kee, Micah Daniel, Flores, Holly, Garrett, Morgan, Rucker, Brayden   +6 more
openaire   +1 more source

From heparins to factor Xa inhibitors and beyond

European Journal of Clinical Investigation, 2005
AbstractDespite some disadvantages, unfractionated heparin (UFH) and oral anticoagulants have been the only anticoagulants for prophylaxis and therapy of thromboembolic disorders for several decades.Based on the increasing knowledge of the structure and pharmacology of heparin, low molecular weight heparins (LMWH) have been developed in the 1980s ...
openaire   +2 more sources

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

Expert Opinion on Pharmacotherapy, 2004
Fondaparinux (Arixtra) is the first of a new class of antithrombotic compounds - Factor Xa inhibitors. This synthetic pentasaccharide acts by inhibiting Factor Xa selectively. Its efficacy and safety have been demonstrated in animal models of venous and arterial thromboses and bleeding risk.
openaire   +2 more sources

Inhibitors of Thrombin and Factor Xa

2000
In medicine today, much effort is being made to develop new protease inhibitors for use as anticoagulants in multiple disease states. Deep venous thrombosis and pulmonary embolism, in particular, are major medical problems in the developed world. Similarly, myocardial infarction, stroke, and peripheral vascular disease are arterial thromboses for which
openaire   +1 more source

Fondaparinux sodium: A selective inhibitor of factor Xa

American Journal of Health-System Pharmacy, 2001
The pharmacology and mechanism of action of fondaparinux sodium are described. Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. It has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response.
openaire   +2 more sources

Factor Xa inhibitors

Expert Opinion on Therapeutic Patents, 1999
F Al-Obeidi, JA Ostrem
openaire   +1 more source

Factor Xa Inhibitors

2004
Jeanine M, Walenga, Walter P, Jeske, Debra, Hoppensteadt, Jawed, Fareed   +3 more
openaire   +2 more sources

Factor Xa inhibitors (Berlex).

IDrugs : the investigational drugs journal, 2005
Berlex Biosciences is investigating several series of Factor Xa inhibitors aimed at the prevention and treatment of thrombotic disorders [297584]. Some compounds are based on the structure of ZK-805412, a Z,Z-2,7-bis(dibenzylidene)cycloheptanone, which showed nanomolar Factor Xa inhibitor potency [301618].
openaire   +1 more source

Inhibitors of Factor Xa

Expert Opinion on Therapeutic Patents, 2001
openaire   +1 more source